Wellington Management Group LLP Acquires 4,497,950 Shares of Amicus Therapeutics, Inc. (NASDAQ:FOLD)

Wellington Management Group LLP increased its holdings in Amicus Therapeutics, Inc. (NASDAQ:FOLD - Free Report) by 18.8% in the 4th quarter, according to the company in its most recent filing with the Securities and Exchange Commission (SEC). The institutional investor owned 28,461,994 shares of the biopharmaceutical company's stock after acquiring an additional 4,497,950 shares during the quarter. Wellington Management Group LLP owned about 9.26% of Amicus Therapeutics worth $268,112,000 as of its most recent filing with the Securities and Exchange Commission (SEC).

A number of other large investors also recently bought and sold shares of the business. denkapparat Operations GmbH bought a new stake in Amicus Therapeutics in the fourth quarter worth $171,000. Norges Bank purchased a new stake in Amicus Therapeutics in the fourth quarter worth approximately $29,033,000. Prudential Financial Inc. grew its position in Amicus Therapeutics by 4.6% in the 4th quarter. Prudential Financial Inc. now owns 479,449 shares of the biopharmaceutical company's stock worth $4,516,000 after purchasing an additional 21,000 shares during the period. Vanguard Group Inc. grew its position in Amicus Therapeutics by 1.6% in the 4th quarter. Vanguard Group Inc. now owns 29,258,963 shares of the biopharmaceutical company's stock worth $275,619,000 after purchasing an additional 458,143 shares during the period. Finally, Fox Run Management L.L.C. raised its stake in Amicus Therapeutics by 93.1% during the 4th quarter. Fox Run Management L.L.C. now owns 62,570 shares of the biopharmaceutical company's stock valued at $589,000 after buying an additional 30,162 shares during the last quarter.

Amicus Therapeutics Price Performance

NASDAQ:FOLD traded down $0.50 during trading hours on Friday, hitting $7.50. 3,184,754 shares of the stock traded hands, compared to its average volume of 2,535,352. The company has a market cap of $2.30 billion, a price-to-earnings ratio of -41.67, a price-to-earnings-growth ratio of 1.51 and a beta of 0.79. Amicus Therapeutics, Inc. has a 1 year low of $7.39 and a 1 year high of $12.65. The stock has a 50 day moving average price of $9.12 and a 200 day moving average price of $9.84. The company has a quick ratio of 2.42, a current ratio of 3.39 and a debt-to-equity ratio of 2.01.

Wall Street Analysts Forecast Growth

Several brokerages recently commented on FOLD. Needham & Company LLC reiterated a "hold" rating on shares of Amicus Therapeutics in a research report on Thursday, February 20th. Wells Fargo & Company reduced their price target on shares of Amicus Therapeutics from $18.00 to $17.00 and set an "overweight" rating for the company in a research report on Thursday, February 20th. Morgan Stanley reissued an "equal weight" rating and issued a $12.00 price objective (down previously from $17.00) on shares of Amicus Therapeutics in a report on Friday, December 13th. Cantor Fitzgerald reaffirmed an "overweight" rating and set a $21.00 target price on shares of Amicus Therapeutics in a report on Wednesday, January 15th. Finally, StockNews.com downgraded shares of Amicus Therapeutics from a "buy" rating to a "hold" rating in a research report on Thursday, February 20th. Three investment analysts have rated the stock with a hold rating and seven have assigned a buy rating to the company. According to MarketBeat, Amicus Therapeutics currently has an average rating of "Moderate Buy" and an average price target of $16.75.

About Amicus Therapeutics

Amicus Therapeutics, Inc, a biotechnology company, focuses on discovering, developing, and delivering medicines for rare diseases. Its commercial product and product candidates include Galafold, an oral precision medicine for the treatment of adults with a confirmed diagnosis of Fabry disease and an amenable galactosidase alpha gene variant; and Pombiliti + Opfolda, for the treatment of late onset.